ArticleHaematologica2019
Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.
Abstract readLetter
In one paragraph
Article in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Dual Targeting of Pim and PI3 Kinases in Mature T-Cell Lymphoma.European journal of haematology · 2025Article
- PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL.NPJ precision oncology · 2024Article
- NUP98-BPTF promotes oncogenic transformation through PIM1 upregulation.Cancer medicine · 2024Article
- Emerging Epigenetic and Posttranslational Mechanisms Controlling Resistance to Glucocorticoids in Acute Lymphoblastic Leukemia.HemaSphere · 2023Review
- Targeting Pim kinases in hematological cancers: molecular and clinical review.Molecular cancer · 2023Review
- SOHO State of the Art Updates and Next Questions | Novel Approaches to Pediatric T-cell ALL and T-Lymphoblastic Lymphoma.Clinical lymphoma, myeloma & leukemia · 2022Review
- Ruxolitinib as a Novel Therapeutic Option for Poor Prognosis T-LBL Pediatric Patients.Cancers · 2021Article
- Review
- T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies.Blood cancer discovery · 2021Review
- PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis.Molecular cancer therapeutics · 2020Article
- Design of a Comprehensive Fluorescence in Situ Hybridization Assay for Genetic Classification of T-Cell Acute Lymphoblastic Leukemia.The Journal of molecular diagnostics : JMD · 2020Article
- The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL.British journal of cancer · 2020Review
- Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials.Science translational medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Renate De SmedtDepartment of Biomolecular Medicine, Ghent University, Belgium.
Sofie PeirsDepartment of Biomolecular Medicine, Ghent University, Belgium.
Julie MorscioDepartment of Biomolecular Medicine, Ghent University, Belgium.
Filip MatthijssensDepartment of Biomolecular Medicine, Ghent University, Belgium.
Juliette RoelsDepartment of Biomolecular Medicine, Ghent University, Belgium.
Lindy ReunesDepartment of Biomolecular Medicine, Ghent University, Belgium.
Beatrice LintermansDepartment of Biomolecular Medicine, Ghent University, Belgium.
Steven GoossensDepartment of Biomolecular Medicine, Ghent University, Belgium.
Tim LammensCancer Research Institute Ghent (CRIG), Belgium.
Nadine Van RoyDepartment of Biomolecular Medicine, Ghent University, Belgium.
Aurore TouzartDepartment of Hematology, APHP-Hôpital Necker, Paris, France.
Silvia JenniDepartment of Oncology, and Children's Research Center, University Children's Hospital Zurich, Switzerland.
Yi-Chien TsaiDepartment of Oncology, and Children's Research Center, University Children's Hospital Zurich, Switzerland.
Federica LovisaDepartment of Woman's and Child's Health, Hematology-Oncology Laboratory, Istituto di Ricerca Pediatrica (IRP) and University of Padova, Italy.
Lara MussolinDepartment of Woman's and Child's Health, Hematology-Oncology Laboratory, Istituto di Ricerca Pediatrica (IRP) and University of Padova, Italy.
Valentina SerafinDepartment of Woman's and Child's Health, Hematology-Oncology Laboratory, Istituto di Ricerca Pediatrica (IRP) and University of Padova, Italy.
Filip Van NieuwerburghLaboratory of Pharmaceutical Biotechnology, Ghent University, Belgium.
Dieter DeforceLaboratory of Pharmaceutical Biotechnology, Ghent University, Belgium.
Anne UyttebroeckDepartment of Pediatric Hematology-Oncology, University Hospitals Leuven, Belgium.
Thomas TousseynTranslational Cell and Tissue Research laboratory, KU Leuven, Belgium.
Birgit BurkhardtDepartment of Pediatric Hematology and Oncology, University of Münster, Germany.
Wolfram KlapperDepartment of Pathology, Hematopathology Section, UKSH Campus Kiel, Germany.
Barbara De MoerlooseCancer Research Institute Ghent (CRIG), Belgium.
Yves BenoitCancer Research Institute Ghent (CRIG), Belgium.
Elizabeth MacintyreDepartment of Hematology, APHP-Hôpital Necker, Paris, France.
Jean-Pierre BourquinDepartment of Oncology, and Children's Research Center, University Children's Hospital Zurich, Switzerland.
Giuseppe BassoDepartment of Woman's and Child's Health, Hematology-Oncology Laboratory, Istituto di Ricerca Pediatrica (IRP) and University of Padova, Italy.
Benedetta AccordiDepartment of Woman's and Child's Health, Hematology-Oncology Laboratory, Istituto di Ricerca Pediatrica (IRP) and University of Padova, Italy.
Beat BornhauserDepartment of Oncology, and Children's Research Center, University Children's Hospital Zurich, Switzerland.
Jules MeijerinkThe Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Peter VandenbergheDepartment of Hematology, University Hospitals Leuven, Belgium.
Pieter Van VlierbergheDepartment of Biomolecular Medicine, Ghent University, Belgium pieter.vanvlierberghe@ugent.be.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Precursor T-Cell Lymphoblastic Leukemia-LymphomaProto-Oncogene Proteins c-pim-1Cell Line, TumorDrug Screening Assays, AntitumorHumansProtein Kinase InhibitorsPIM1 protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-pim-1
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.